2025 - A year of Strategic Momentum

The 2025 year marked a defining year for EFEVRE TECH—one not focusing on promises, but on execution. Across software, deep-tech hardware, EU-funded innovation, and strategic partnerships, this year validated our vision: to transform how advanced technology is designed, deployed, trusted in real-world scientific and industrial environments.

From Concept to Completion: Software Platforms

In 2025, our two software website platforms, VITALE and BioSkepsis AI, both have reached full maturity and both platforms have successfully exited the testing phase.

1. VITALE was specifically engineered to address these challenges by offering an all-in-one solution for laboratory automation and data management. Whether it's automating routine tasks, ensuring handling of samples, or providing real-time insights into ongoing experiments, VITALE empowers researchers to focus on what truly matters: groundbreaking discoveries. VITALE was fully developed, rigorously tested by early adopters in real-life scenarios, and successfully completed and submitted as an EU-funded project. The platform demonstrated its capacity to support advanced biomedical workflows, knowledge extraction, and decision support at scale.

2. BioSkepsis Artificial Intelligence comes from bio = biology and skepsis = a Greek word that means critical thinking. BioSkepsis AI is an advanced AI-driven research intelligence platform that retrieves millions of new scientific articles from PubMed, to avoid life-science researchers to spend countless hours sifting through abstracts, cross-referencing terms, and validating findings across multiple sources. It is designed to transform the way researchers, clinicians, and biotech innovators interact with biomedical knowledge. BioSkepsis AI offers a wide range of applications for life-science researchers, clinicians, and biotech innovators. In drug discovery, this platform helps identify molecular pathways connected to emerging therapies, enabling faster and more targeted development efforts. For disease research, it uncovers complex connections between genes, proteins, and disease biomarkers, giving scientists a clearer understanding of disease mechanisms. In diagnostics development, BioSkepsis AI accelerates the validation of candidate markers by instantly summarizing literature evidence across thousands of publications. It also transforms the process of conducting literature reviews, providing structured, AI-assisted insights that save weeks of manual effort. ​

While this milestone closes an important chapter in 2025, it also sets the stage for what comes next in 2026 to introduce new releases that build on this foundation in unexpected and impactful ways.

Hardware Innovation Validated by the Market

A major highlight of the year was the commercial validation of our deep-tech hardware efforts. AMGEL4TT, our compact real-time laboratory device, achieved its first commercial sale to the Cancer Molecular Diagnostics Laboratory of the University of Cambridge.

The Technology Transfer device is a cutting-edge, modular laboratory automation workstation designed to revolutionize the way novel molecular diagnostic applications transition from laboratory to market. Whether you’re in academia, an R&D company, or a laboratory, AMGEL4TT streamlines the entire process, ensuring your innovations don’t just remain in research.​ This milestone represents more than a sale transaction it is independent confirmation that our engineering, design, and performance standards meet the expectations of one of the world’s leading research institutions.

Growing a Trusted Research Community

Our commitment to collaborative innovation continued through LIFESPIRIT, which managed to reach its first 50 active member organizations in 2025. This growing network of laboratories, research centers, and industry stakeholders reflects a shared demand for interoperable, transparent, and AI-enabled research tools.

EU Projects, Pilots, and Partnerships

We marked the successful completion of the VITALE EU-funded project, alongside a year rich in:

• 1:1 live demonstration meetings and hands-on pilot testing

• Remote webinars, workshops, and trainings

• Strategic collaborations with academic, industrial, and innovation partners

Closing 2025 and Looking Ahead

As we close 2025, EFEVRE TECH stands on a position of strength shaped by execution and validation. Our software platforms have moved decisively beyond development into tested, deployable solutions; our hardware innovation has been proven in real research environments; and our growing community reflects a shared commitment to rigorous, technology-driven progress. Most importantly, the partnerships formed and strengthened throughout the year are grounded in trust, collaboration, and shared ambition.

The year ahead will build on this momentum with purpose. In 2026, our focus turns to expansion, introducing new releases, deepening integrations across platforms, and scaling impact across industry and research ecosystems. Each step forward will continue to be guided by real-world needs, measurable outcomes, and a disciplined approach to innovation.

We extend our sincere appreciation to our clients, partners, investors, and collaborators for the confidence they placed in our work throughout this journey. 2025 was a year of delivery and proof. 2026 will be a year of acceleration and transforming validated foundations into lasting impact.